Algernon Pharmaceuticals Inc.
AGNPF
$0.0488
-$0.0022-4.31%
OTC PK
| 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -44.68% | -42.15% | -58.31% | -54.47% | -49.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -57.67% | -42.36% | -54.49% | -54.39% | -42.16% |
| Operating Income | 57.67% | 42.36% | 54.49% | 54.39% | 42.16% |
| Income Before Tax | 105.57% | 93.25% | 92.52% | 59.65% | 17.41% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 105.57% | 93.25% | 92.52% | 59.65% | 17.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 105.57% | 93.25% | 92.52% | 59.65% | 17.41% |
| EBIT | 57.67% | 42.36% | 54.49% | 54.39% | 42.16% |
| EBITDA | 57.81% | 42.30% | 54.56% | 54.45% | 42.31% |
| EPS Basic | 107.88% | 94.72% | 92.71% | 85.76% | 64.20% |
| Normalized Basic EPS | 72.98% | 66.69% | 74.50% | 92.79% | 70.82% |
| EPS Diluted | 105.57% | 92.95% | 91.51% | 84.81% | 64.11% |
| Normalized Diluted EPS | 72.29% | 66.18% | 74.17% | 92.58% | 70.82% |
| Average Basic Shares Outstanding | 30.52% | 37.18% | 32.34% | 129.62% | 127.90% |
| Average Diluted Shares Outstanding | 31.19% | 37.94% | 33.17% | 130.95% | 127.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |